ArticleJournal of drug targeting2011
Rational design, fabrication, characterization and in vitro testing of biodegradable microparticles that generate targeted and sustained transgene expression in HepG2 liver cells.
Article in Journal of drug targeting, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 16 citations in OpenAlex.
- Biomaterial-based delivery systems of nucleic acid for regenerative research and regenerative therapy.Regenerative therapy · 2019Review
- Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.The AAPS journal · 2018Review
- A Pilot Study Evaluating Combinatorial and Simultaneous Delivery of Polyethylenimine-Plasmid DNA Complexes Encoding for VEGF and PDGF for Bone Regeneration in Calvarial Bone Defects.Current pharmaceutical biotechnology · 2015Article
- Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses.Human vaccines & immunotherapeutics · 2013Review
- Optimized dextran-polyethylenimine conjugates are efficient non-viral vectors with reduced cytotoxicity when used in serum containing environments.International journal of pharmaceutics · 2012Article
- Poly(galactaramidoamine) is an efficient cationic polymeric non-viral vector with low cytotoxicity for transfecting human embryonic kidney (HEK293) and murine macrophage (RAW264.7) cells.Pharmaceutical development and technologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Poly(lactide-co-glycolide) (PLGA) microparticles have significant potential for sustained delivery of plasmid DNA (pDNA). However, unmodified PLGA microparticles have poor transfection efficiencies. In this study, we use several approaches to enhance the transfection efficiencies of PLGA microparticles in a HepG2 liver cell line. Polyethylenimine (PEI) is used to condense the pDNA prior to loading into the PLGA microparticles. This provides enhanced loading efficiencies and greater protection to the pDNA during the entrapment process. In addition, the pDNA used (ApoE) incorporates a hybrid liver-specific murine albumin enhancer/α1 antitrypsin promoter (AlbE/hAAT) to enhance transgene expression in human liver (HepG2) cells. The percentage of surfactant used in the preparation of the microparticles, the polymer composition of the PLGA, the ratio of the PEI to pDNA (N/P), the structure of the PEI and the potential utility of a galactose targeting ligand were then investigated to further optimize the efficacy of the cationic microparticle non-viral delivery system in transfecting HepG2 cells. For each PLGA PEI-pDNA microparticle formulation prepared, we evaluated particle size, ζ-potential, loading of pDNA, cytotoxicity, and transgene expression in HepG2 cells and control human embryonic kidney (HEK293) and monkey African green kidney fibroblast-like (COS7) cells. Loading PLGA particles with PEI-ApoE pDNA complexes resulted in a significant reduction in particle size when compared to PLGA microparticles loaded with ApoE pDNA alone. Scanning electron microscopy images showed that all the particle formulations were smooth and spherical in appearance. Incorporation of the cationic PEI in the PLGA particles changed the ζ-potential from negative to positive. Complexing PEI with ApoE pDNA increased the loading efficiency of the ApoE pDNA into the PLGA microparticles. The cytotoxicity of PLGA particles loaded with PEI-ApoE pDNA complexes was similar to PLGA particles loaded with ApoE pDNA alone. The transfection efficiency of all particle formulations prepared with ApoE pDNA was significantly higher in HepG2 cells when compared to HEK293 and COS7 cell lines. The release of PEI-pDNA complexes from particles prepared with different PLGA polymer compositions including PLGA 50-50, PLGA 75-25, and PLGA 85-15 was sustained in all cases but the release profile was dependent on the polymer composition. Transmission electron microscopy images showed that PEI-pDNA complexes remained structurally intact after release. The optimum formulation for PLGA particles loaded with PEI-ApoE pDNA complexes was prepared using 2% polyvinyl alcohol, 50-50 PLGA compositions and N/P ratios of 5-10. Strong sustained transgene expression in HepG2 cells was generated by PLGA PEI-ApoE pDNA particles up to the full 13 days tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.